Literature DB >> 27179217

Histopathological comparison of Kearns-Sayre syndrome and PGC-1α-deficient mice suggests a novel concept for vacuole formation in mitochondrial encephalopathy.

L Szalardy, M Molnar, R Torok, D Zadori, L Vecsei, P Klivenyi, P Liberski, G G Kovacs1.   

Abstract

Despite the current hypotheses about myelinic and astrocytic ion-dyshomeostasis underlying white (WM) and grey matter (GM) vacuolation in mitochondrial encephalopathies, there is a paucity of data on the exact mechanism of vacuole formation. To revisit the concepts of vacuole formation associated with mitochondrial dysfunction, we performed a comparative neuropathological analysis in Kearns-Sayre syndrome (KSS) and full-length peroxisome proliferator-activated receptor-g coactivator-1a (FL-PGC-1a)-deficient mice, a recently proposed morphological model of mitochondrial encephalopathies. Brain tissues from an individual with genetically proven KSS (22-year-old man) and aged FL-PGC-1a-deficient and wild-type (male, 70-75-week-old) mice were analysed using ultrastructural and immunohistochemical methods, with a specific focus on myelin-related, oligodendroglial, axonal and astrocytic pathologies. Besides demonstrating remarkable similarities in the lesion profile of KSS and FL-PGC-1a-deficient mice, this study first provides morphological evidence for the identical origin of WM and GM vacuolation as well as for the presence of intracytoplasmic oligodendroglial vacuoles in mitochondriopathies. Based on these observations, the paper proposes a theoretical model for the development of focal myelin vacuolation as opposed to the original concepts of intramyelin oedema. Placing oligodendrocytes in the centre of tissue lesioning in conditions related to defects in mitochondria, our observations support the rationale for cytoprotective targeting of oligodendrocytes in mitochondrial encephalopathies, and may also have implications in brain aging and multiple sclerosis, as discussed.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27179217     DOI: 10.5114/fn.2016.58911

Source DB:  PubMed          Journal:  Folia Neuropathol        ISSN: 1509-572X            Impact factor:   2.038


  5 in total

1.  Increasing N-acetylaspartate in the Brain during Postnatal Myelination Does Not Cause the CNS Pathologies of Canavan Disease.

Authors:  Abhilash P Appu; John R Moffett; Peethambaran Arun; Sean Moran; Vikram Nambiar; Jishnu K S Krishnan; Narayanan Puthillathu; Aryan M A Namboodiri
Journal:  Front Mol Neurosci       Date:  2017-06-02       Impact factor: 5.639

2.  Microbial Neuraminidase Induces a Moderate and Transient Myelin Vacuolation Independent of Complement System Activation.

Authors:  Pablo Granados-Durán; María Dolores López-Ávalos; Manuel Cifuentes; Margarita Pérez-Martín; María Del Mar Fernández-Arjona; Timothy R Hughes; Krista Johnson; B Paul Morgan; Pedro Fernández-Llebrez; Jesús M Grondona
Journal:  Front Neurol       Date:  2017-03-07       Impact factor: 4.003

3.  Non-motor Behavioral Alterations of PGC-1α-Deficient Mice - A Peculiar Phenotype With Slight Male Preponderance and No Apparent Progression.

Authors:  Levente Szalardy; Mate F Molnar; Denes Zadori; Edina K Cseh; Gabor Veres; Gabor G Kovacs; Laszlo Vecsei; Peter Klivenyi
Journal:  Front Behav Neurosci       Date:  2018-08-27       Impact factor: 3.558

4.  Neuropathology of SCA34 showing widespread oligodendroglial pathology with vacuolar white matter degeneration: a case study.

Authors:  Kokoro Ozaki; Takashi Irioka; Toshiki Uchihara; Akane Yamada; Ayako Nakamura; Takamasa Majima; Susumu Igarashi; Hiroshi Shintaku; Mayumi Yakeishi; Yukio Tsuura; Yasushi Okazaki; Kinya Ishikawa; Takanori Yokota
Journal:  Acta Neuropathol Commun       Date:  2021-10-24       Impact factor: 7.801

5.  Azetidine-2-Carboxylic Acid-Induced Oligodendrogliopathy: Relevance to the Pathogenesis of Multiple Sclerosis.

Authors:  Raymond A Sobel; Megan Albertelli; Julian R Hinojoza; Mary Jane Eaton; Kevin V Grimes; Edward Rubenstein
Journal:  J Neuropathol Exp Neurol       Date:  2022-05-20       Impact factor: 3.148

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.